文献速递生殖医学

采用单基因病与染色体非整倍体植入前遗传学检测的体外受精周期与仅采用非整倍体检测周期的非整倍体率及获得可用胚胎可能性比较

Aneuploidy rates and likelihood of obtaining a usable embryo for transfer among in vitro fertilization cycles using preimplantation genetic testing for monogenic disorders and aneuploidy compared with in vitro fertilization cycles using preimplantation genetic testing for aneuploidy alone.
PubMed 文献 · Fertil Steril · 2024-07-26

这项回顾性队列研究纳入2019年11月至2023年3月单一生殖遗传学实验室的72522个IVF周期,其中4255个周期(5.9%)采用PGT-M+PGT-A,68267个周期(94.1%)仅采用PGT-A。按年龄分层的非整倍体率在两组间无显著差异;在≤40岁患者中,除常染色体隐性病38-40岁组和X连锁隐性病35-37岁组外,PGT-M+PGT-A周期获得可用胚胎的可能性显著低于仅PGT-A周期。

要点

  • PGT-M+PGT-A与仅PGT-A周期的年龄分层非整倍体率无显著差异。
  • ≤40岁患者采用PGT-M+PGT-A获得可用胚胎的可能性显著低于仅PGT-A。
  • 常染色体显性疾病患者<43岁时获得可用胚胎的可能性最低。

核心结论

  • 采用PGT-M+PGT-A的IVF周期与仅采用PGT-A的周期具有相似的年龄特异性非整倍体率。
  • ≤40岁患者采用PGT-M+PGT-A的周期获得可用胚胎的可能性显著低于仅采用PGT-A的周期。

研究设计与样本

  • 回顾性队列研究,纳入2019年11月至2023年3月单一生殖遗传学实验室所有18-45岁接受PGT-A伴或不伴PGT-M的IVF周期。
  • 共纳入72522个IVF周期,其中4255个周期(5.9%)采用PGT-M+PGT-A,68267个周期(94.1%)仅采用PGT-A。

主要发现

  • PGT-M+PGT-A组患者较仅PGT-A组年轻(<35岁:56.1% vs 30.5%)。
  • PGT-M周期主要针对常染色体显性致病变异(42.4%),其次为常染色体隐性(36.5%)、X连锁显性(13.3%)和X连锁隐性(7.5%)。
  • 在<35岁患者中,仅PGT-A周期活检胚胎中位数高于PGT-M+PGT-A周期,其他年龄组两者相当。
  • 按年龄分层的非整倍体率在PGT-M+PGT-A与仅PGT-A周期之间无显著差异。
  • 与仅PGT-A相比,≤40岁患者在所有遗传模式下PGT-M+PGT-A周期获得可用胚胎的可能性显著更低,但常染色体隐性疾病38-40岁组和X连锁隐性疾病35-37岁组除外;>40岁患者两组间无一致差异。

关键数值与推荐

  • 常染色体显性疾病患者<43岁时获得可用胚胎的可能性最低。
  • 所有遗传模式下获得可用胚胎的概率随年龄增长而下降。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare aneuploidy rates among in vitro fertilization (IVF) cycles using preimplantation genetic testing for monogenic disorders (PGT-M) and aneuploidy (PGT-A) compared with IVF cycles using PGT-A alone, and to determine the likelihood of obtaining at least one usable embryo in cycles using PGT-M+PGT-A compared with cycles using PGT-A alone. DESIGN: Retrospective cohort study. SETTING: Single genetics laboratory. PATIENT(S): All IVF cycles for patients aged 18-45 undergoing PGT-A with or without concurrent PGT-M at a single genetics laboratory from November 2019 to March 2023. INTERVENTION(S): Use of PGT-M+PGT-A vs. use of PGT-A alone. MAIN OUTCOME MEASURE(S): Per cycle aneuploidy rate stratified by age, and per cycle likelihood of obtaining at least one usable embryo stratified by age and inheritance pattern of monogenic disease. RESULT(S): A total of 72,522 IVF cycles were included; 4,255 cycles (5.9%) using PGT-M+PGT-A and 68,267 cycles (94.1%) using PGT-A alone. The PGT-M+PGT-A group was younger than the PGT-A alone group (<35 years old: 56.1% vs. 30.5%). The majority of PGT-M cycles were performed for autosomal dominant pathogenic variants (42.4%), followed by autosomal recessive (36.5%), X-linked dominant (13.3%), and X-linked recessive (7.5%). The median number of embryos biopsied was higher in PGT-A alone compared with PGT-M+PGT-A cycles for patients aged <35, but it was equivalent in all other age groups. Age stratified aneuploidy rates did not significantly differ between PGT-M+PGT-A compared with PGT-A alone cycles. The probability of having a usable embryo declined with increasing age across all inheritance patterns. Compared with PGT-A alone, PGT-M+PGT-A cycles for patients aged ≤40 across all inheritance patterns were significantly less likely to yield a usable embryo, except in cycles for autosomal recessive diseases in the 38-40 age group and X-linked recessive diseases in the 35-37 age group. There were no consistent differences seen between groups in patients over 40. Cycles for patients with autosomal dominant diseases had the lowest likelihood of yielding a usable embryo for patients aged <43. CONCLUSION(S): In vitro fertilization cycles using PGT-M+PGT-A have similar age-specific aneuploidy rates to those using PGT-A alone. Cycles for patients ≤40 using PGT-M+PGT-A are significantly less likely to yield a usable embryo compared with those using PGT-A alone.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Martel RA, Lee MB, Schadwell A, et al. Aneuploidy rates and likelihood of obtaining a usable embryo for transfer among in vitro fertilization cycles using preimplantation genetic testing for monogenic disorders and aneuploidy compared with in vitro fertilization cycles using preimplantation genetic testing for aneuploidy alone. Fertil Steril. 2024. PMID: 39069217. doi:10.1016/j.fertnstert.2024.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。